Rizvi Asad A, Thompson Paul D
Division of Cardiology, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
Curr Sports Med Rep. 2002 Apr;1(2):93-9. doi: 10.1007/s11932-002-0056-0.
Hypertrophic cardiomyopathy (HCM) is a genetically determined, primary myocardial disease associated with an increased risk for sudden cardiac death during physical exertion. In the United States, HCM is the most frequent cause of exertion-related sudden cardiac death (SCD). Current recommendations provided by the 26th Bethesda Conference entitled Recommendations for Determining Eligibility for Competition in Athletes with Cardiovascular Abnormalities restrict participation for patients with HCM to sports requiring low levels of dynamic and isometric exertion. Such recommendations are prudent given the association of the disease with disastrous cardiovascular consequences. Nevertheless, because the prognosis of HCM and its risk of sudden death is typified by great variability among patients, these recommendations may be overly restrictive for many patients with this disease, and it is possible that a subset of low-risk patients can be identified who may continue to engage in more vigorous exercise activities. This article presents our current understanding and approach to evaluating and advising athletes with HCM.
肥厚型心肌病（HCM）是一种由基因决定的原发性心肌病，与体力活动期间心脏性猝死风险增加相关。在美国，HCM是与体力活动相关的心脏性猝死（SCD）的最常见原因。第26届贝塞斯达会议发布的题为《心血管异常运动员参赛资格判定建议》的现行建议将HCM患者的参赛限制在需要低水平动态和等长运动的体育项目。鉴于该疾病与灾难性心血管后果相关，这些建议是审慎的。然而，由于HCM的预后及其猝死风险在患者中差异很大，这些建议对许多患有该疾病的患者可能限制过度，并且有可能识别出一部分低风险患者，他们可能继续从事更剧烈的运动活动。本文介绍了我们目前对评估和建议HCM运动员的理解和方法。
